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Objectives. We sought to assess the effects of antithrombotic
therapy after thrombolysis for acute myocardial infarction on
markers of thrombin generation and activity and to determine the
relation of these markers with clinical outcomes.
Background. Thrombin activation and generation often occur
with thrombolysis for acute myocardial infarction. Antithrombotic
regimens have been developed to reduce the resulting thrombotic
complications.
Methods. We sampled plasma markers of thrombin generation
and activity after thrombolysis in 292 patients. We assessed the
relations of these markers with clinical outcomes at 30 days.
Results. Fibrinopeptide A (FPA), a marker of thrombin activity
toward fibrinogen, was elevated at baseline (12.3 ng/ml) and
increased to 18.4 ng/ml by 90 min after streptokinase and
subcutaneous heparin treatment. With intravenous heparin, this
increase was attenuated, but intravenous heparin did not prevent
thrombin generation, as measured by prothrombin fragment 1.2
(F1.2). Heparin level, measured by anti-Xa activity, correlated
with activated partial thromboplastin time (aPTT, r 5 0.62 to
0.67). Thrombin activity, measured by FPA, was as closely related
to aPTT as to the heparin level. Baseline levels of F1.2 were
significantly related to the risk of death or reinfarction at 30 days
(p 5 0.008); values 12 h after enrollment also were related to
30-day mortality (p 5 0.05).
Conclusions. Although intravenous heparin partly suppresses
the increased thrombin activity associated with thrombolysis, it
does not inhibit thrombin generation. The aPTT was as good a
measure of suppression of thrombin activity as the heparin level
itself. Hematologic markers of thrombin generation were found to
be related to the subsequent risk of thrombotic events.
(J Am Coll Cardiol 1998;31:497–505)
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Studies suggest that thrombin activity increases after thrombo-
lytic therapy (1–3) and that heparin can lessen this increase (4).
After alteplase and heparin therapy, infarct-related artery
patency more often occurs in patients with longer activated
partial thromboplastin times (aPTT) (5,6). Although aPTT
measurement has been the standard clinical approach to
estimating the effect of heparin on thrombin inhibition, factors
other than heparin affect aPTT. Fibrinogenolysis, degradation
of factors V and VIII and fibrin degradation products (which
inhibit thrombin activity and fibrin formation) all prolong
aPTT, especially early after thrombolysis (7). Lower levels of
fibrinopeptide A (FPA), the peptide cleaved during the con-
version of fibrinogen to fibrin, and lower levels of thrombin–
antithrombin complex (TAT) also have been associated with
greater infarct-related artery patency after thrombolysis (4–8).
Data correlating plasma hematologic markers during acute
myocardial infarction with later clinical events are lacking.
Between 1990 and 1993, the Global Utilization of Strep-
tokinase and TPA [tissue plasminogen activator—alteplase]
for Occluded Coronary Arteries (GUSTO-I) trial enrolled
41,021 patients with acute myocardial infarction in 15 countries
for a randomized comparison of four thrombolytic treatment
strategies (9). An important aspect of the study was the
comparison of treatments with different degrees of systemic
fibrinolysis and different intensities of adjunctive heparin. The
purposes of this substudy were 1) to evaluate the effects of
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various thrombolytic and heparin regimens on thrombin gen-
eration and activity; 2) to assess the relation of aPTT with
thrombin activity in the setting of thrombolysis; and 3) to
determine the relation of various measures of thrombin activity
with clinical outcomes.
Methods
Participating hospitals. Twelve North American hospitals
(10 in the United States and 2 in Canada) participating in the
GUSTO-I trial enrolled patients into the hemostasis substudy;
eight of these hospitals also participated in the GUSTO-I
angiographic substudy (10).
Patient group. Eligibility criteria for GUSTO-I have been
described (9). Briefly, patients who were within 6 h of symptom
onset of acute myocardial infarction with electrocardiographic
ST segment elevation were eligible if they had no history of
stroke, active bleeding, recent major operation, recent non-
compressible vascular puncture, previous enrollment in the
trial or previous treatment with streptokinase or anistreplase.
Treatments. Patients were randomly assigned to one of
four treatment strategies: streptokinase, 1.5 million U over 1 h,
with subcutaneous heparin, 12,500 U twice daily begun 4 h
after the start of thrombolysis; streptokinase, 1.5 million U
over 1 h, with intravenous heparin; accelerated alteplase, with
a bolus dose of 15 mg followed by an infusion of 0.75 mg/kg
body weight (up to 50 mg) over 30 min and 0.5 mg/kg (up to
35 mg) over the next hour, with intravenous heparin; or the
combination of alteplase, 1.0 mg/kg over 1 h, not to exceed
90 mg, with 10% given as a bolus, and streptokinase, 1.0
million U over 1 h, with intravenous heparin. The intravenous
heparin regimen was a bolus dose of 5,000 U and then
1,000 U/h for $48 h; the investigator could delay the heparin
infusion (not the bolus) until the completion of thrombolytic
therapy if intravenous access was lacking. After ;10,000
patients were enrolled, aPTT was found to be below the target
range in about half of GUSTO-I patients at 24 h, and aPTT
was much more often below the target range in heavy patients.
Thus, the recommendation was made to increase the initial
dose of heparin to 1200 U/h for patients who weighed .80 kg.
Monitoring aPTT and adjusting heparin. The aPTT was
assessed at 6, 12 and 24 h after the start of thrombolytic
therapy in all patients assigned to intravenous heparin. The
heparin dose was adjusted according to a nomogram to achieve
a target aPTT range of 60 to 85 s. Based on the 6- and 12-h
aPTTs, the heparin dose was to be titrated upward for aPTTs
,60 s. However, because the systemic fibrinolytic state often
induced by plasminogen activators is known to prolong aPTT
early after thrombolysis, the heparin dose was not to be titrated
downward based on 6- or 12-h aPTTs .85 s.
Sample acquisition and processing. Blood samples were to
be drawn at baseline (before thrombolysis) and 12 and 24 h
after the start of thrombolysis. In addition, angiographic
substudy centers drew additional samples 90 min after the start
of thrombolysis. At centers not involved in the angiographic
substudy, additional samples were drawn at 6 and 36 h, and at
one center (Scarborough General Hospital, Scarborough, On-
tario, Canada) at 6 and 48 h and then daily until heparin was
discontinued.
Blood samples were collected for assay of heparin levels
(anti-Xa, anti-IIa), thrombin generation (prothrombin frag-
ment 1.2 [F1.2]), thrombin activity (FPA), thrombin inactiva-
tion (TAT) and fibrinogen and fibrin breakdown (fibrinogen,
D-dimer).
Samples were collected through either separate venipunc-
tures or a large-bore arterial sheath (for patients enrolled in
the angiographic substudy) using a 21-gauge butterfly Vacu-
tainer collection set (Becton Dickinson) and 12-in. (30.5-cm)
tubing with multiple Luer adapters. For all phlebotomies, the
first 5 ml of blood was discarded.
Two tubes were collected at all time points: a 4.5-ml, 3.8%
sodium citrate tube (Becton Dickinson) and a 5-ml tube with
lyophilized D-phenyl-prolyl-arginyl-chloromethylketone (2.5 3
1025 mol/liter, final concentration) (Haematologic Technolo-
gies, Inc.), EDTA (4.5 mmol/liter, final concentration) and
aprotinin (150 kallikrein inhibitor U/ml, final concentration)
(11). The samples were immediately placed on ice and spun
within 1 h of sample collection at 2,000 to 3,000g for 10 to
15 min at room temperature. The supernatant was immediately
frozen at 220° to 270° C.
Laboratory assays. All assays were performed at the core
laboratory (University of Vermont). Levels of FPA were
quantified using the “RIA-mat” FPA radioimmunoassay (Byk-
Sangtec, Marburg, Germany) using bentonite to absorb plasma
fibrinogen. The FPA antibody used has a cross reactivity to
fibrinogen of ,4% and a lower detection limit of 0.1 ng/ml.
The reference range for our laboratory was 1.0 to 7.1 ng/ml
(n 5 24). Prothrombin F1.2 was determined using a two-site,
enzyme-linked immunosorbent assay (Baxter Dade Diagnos-
tics, Inc.) using monoclonal anti-F1.2 antibodies directed
against antigenic sites not available in the native prothrombin
molecule, and the reference range was 0.03 to 0.38 nmol/liter
(n 5 16). The interassay coefficient of variation for the FPA
assay was 7.2% and for the F1.2 assay, 10.0%.
Levels of TAT were measured by an enzyme-linked immu-
nosorbent assay (Diagnostica Stago, Inc.) that uses an antibody
to modified antithrombin III (AT-III) found in the AT-III
protease complexes. The major component of the AT-III
protease complexes is the combination of AT-III with throm-
bin, and throughout this report the results of this assay are
referred to as thrombin–antithrombin complexes, or TAT. The
Abbreviations and Acronyms
aPTT 5 activated partial thromboplastin time
AT-III 5 antithrombin III
F1.2 5 prothrombin fragment 1.2
FPA 5 fibrinopeptide A
GUSTO-I 5 Global Utilization of Streptokinase
and TPA for Occluded Coronary
Arteries
TAT 5 thrombin–antithrombin complex
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reference range for this assay is ,20 ng/ml, and the interassay
coefficient of variation is 8%.
Heparin levels were measured by anti-Xa concentration by
the amidolytic method (American Bioproducts). The interas-
say coefficient of variation for the assay was 8.4%.
Statistical analysis. To identify and remove values most
likely representing artifact, samples for which the FPA value
was markedly elevated—defined arbitrarily but prospectively
as $50 ng/ml, before any analysis of correlation with out-
comes—were removed from the analysis (12). This comprised
60 (9.5%) of the 12- and 24-h samples. All hematologic data
for a patient at the time point when the artifact occurred were
removed from the analysis. The pattern of the relations
between marker levels and outcomes did not change substan-
tially when the analyses were repeated using all samples.
Descriptive statistics included median values with inter-
quartile ranges as measures of central tendency and variation
for continuous variables and frequencies for categoric vari-
ables. Analyses of the effect of thrombolytic regimen for each
of the hematologic factors were performed using univariate
repeated-measures techniques. This is a special type of general
linear model in which each patient at each time point is
included as a new observation into the model. In this way, we
can model the amount of variation that occurs within as well as
between patients. The variables included in the model as
predictors were the thrombolytic regimen, the time of the
measure drawn (baseline to .24 h) and the interaction be-
tween time and thrombolytic regimen. From each model, we
were able to obtain an overall, or global, test of the effect of
treatment on outcome. If the global test was not statistically
significant at p , 0.05, then no further testing was performed
on that outcome. If the global test was significant, then the
individual tests were performed to see where the differences
occurred. We recognize that this can produce many analyses if
the global tests are significant. Because problems can occur
with multiple comparisons within and between the several
outcomes evaluated, all interpretations of results should be
considered exploratory and designed primarily to generate
questions for further studies.
Spearman correlations were calculated to identify relations
between the factors themselves. Plots of the average aPTT
versus FPA level for deciles of FPA at 12 and 24 h illustrated
the relation between these factors. Similar plots were created
for aPTT versus F1.2 and TAT.
The relation of FPA and F1.2 to 30-day mortality, reinfarc-
tion and death or nonfatal reinfarction were evaluated using
logistic regression techniques. Because the relations were not
linear, spline transformations were used to properly model the
relation seen.
Results
Baseline characteristics, treatment assignments and out-
comes for patients enrolled in this substudy, compared with
those for patients not in the substudy, are shown in Table 1.
The overall baseline characteristics were similar, with the
exception of a higher percentage of the substudy patients being
enrolled in the United States. In the hemostasis substudy,
there was a higher percentage of patients of African descent
and fewer patients with diabetes than in the main trial cohort.
Baseline anti-Xa samples and cumulative distributions of
FPA. Heparin levels at baseline, measured by anti-Xa activity,
were ,0.10 U in 85.6% of patients, indicating that although
samples were drawn in the vast majority of patients before
heparin was given, some patients had received heparin before
enrollment. Among patients assigned to receive streptokinase
and subcutaneous heparin, the median anti-Xa activity was
0.01 U at 90 min and 0.06 U at 6 h.
To determine whether having arterial sheaths in place
appeared to artifactually increase FPA levels, we compared the
samples from the patients in the angiographic substudy, who
had arterial sheaths in place for the first 18 to 24 h, with those
from patients not in this substudy, who generally did not have
sheaths in place. We found no evidence of higher median FPA
levels among patients with sheaths versus without sheaths in
place either at 12 h (6.35 vs. 8.70 ng/ml) or at 24 h (6.90 vs.
8.40 ng/ml).
Hemostasis markers according to treatment group and
time. Figure 1, A–C illustrates FPA, F1.2 and TAT levels at
different times according to treatment assignment. Baseline
levels of FPA, F1.2 and TAT were all elevated. For patients
treated with streptokinase and subcutaneous heparin (begin-
ning 4 h after thrombolytic therapy), there was an abrupt
increase in the FPA level early after thrombolysis, in contrast
to patients assigned intravenous heparin, who had a steady
decrease in the FPA level over the next 12 h. When examining
the 49 patients treated with streptokinase who had sequential
Table 1. Baseline Characteristics and Clinical Outcomes of Patients
Who Had 12-h Samples and Fibrinopeptide A Levels , 50 ng/ml
Hemostasis
Substudy
(n 5 293)
Nonhemostasis
Substudy
(n 5 40,738)
Age (yr) 62 (51, 71) 62 (52, 70)
Female 28 25
Current smoking 41 43
Diabetes 11 15
Hypertension 42 38
White 90 92
African American 6 3
Enrolled in United States 72 56
Time to treatment (h) 2.6 (1.9, 3.8) 2.8 (2.0, 3.9)
Systolic blood pressure (mm Hg) 126 (110, 140) 130 (112, 144)
Pulse (beats/min) 72 (62, 83) 74 (62, 86)
Killip class I or II 99 98
Killip class III or IV 1 2
Anterior infarction 38 39
Clinical outcomes
30-day mortality 5.0 7.0
Stroke 1.8 1.4
Reinfarction 5.3 4.0
Moderate or severe hemorrhage 18.7 12.6
Data presented are percent of patients or median (25th, 75th percentiles).
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samples at baseline and at 90 min, there was an 8.4-ng/ml
increase in FPA in patients treated with streptokinase and
delayed subcutaneous heparin, compared with a 0.4-ng/ml
increase in patients treated with streptokinase and intravenous
heparin (p 5 0.03). Levels of F1.2 were elevated in the first
24 h, regardless of intravenous heparin administration. Levels
Figure 1. FPA (A), F1.2 (B) and
TAT (C) at baseline, 90 min, 6 h,
12 h, 24 h and 36 h, according to
treatment group: streptokinase (SK)
with subcutaneous (SubQ) heparin
(open box), streptokinase with in-
travenous (IV) heparin (box with
diagonal lines), accelerated t-PA
with intravenous heparin (cross-
hatched box) and combination
(Combo) streptokinase and t-PA
with intravenous heparin (solid
box). The horizontal bar in each
box is the median value; the upper
and lower borders of the box are
the 25th and 75th percentiles; and
the vertical whisker lines represent
the 5th to 95th percentiles. All six
markers changed as a function of
time (p , 0.0001). Global tests of
differences according to treatment
assignment were statistically signif-
icant for FPA (p 5 0.03) and TAT
(p 5 0.009).
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of TAT also rose after thrombolysis, independent of intrave-
nous heparin therapy. Over the first 24 h, TAT levels were
lower after treatment with streptokinase and subcutaneous
versus intravenous heparin (p 5 0.016) and after treatment
with alteplase and intravenous heparin versus streptokinase
and intravenous heparin (p 5 0.007).
As expected, fibrinogen levels were lower during the first
24 h among patients treated with streptokinase rather than
with alteplase. Median (25th, 75th percentiles) nadir fibrino-
gen levels, which occurred at 90 min, were 20 mg/dl (20, 25) for
streptokinase with subcutaneous heparin, 27 mg/dl (20, 48) for
streptokinase with intravenous heparin, 114 mg/dl (67, 230) for
accelerated alteplase and 20 mg/dl (20, 32) for the combination
thrombolytic regimen. D-Dimer levels (25th, 75th percentiles)
were higher 90 min after treatment with accelerated alteplase,
1,305 mg/ml (555, 2,350) versus streptokinase, 835 mg/ml (330,
1,790) (p 5 0.058), but were lower by 12 h: 675 mg/ml (285,
1,670) for alteplase and 1,075 mg/ml (515, 2,690) for streptoki-
nase (p 5 0.001).
Correlation of heparin levels and aPTT with hemostasis
markers. Relations of FPA, F1.2 and TAT levels with aPTT
are shown in Figure 2, with correlation coefficients of these and
other relations shown in Table 2. As expected, there was a
significant relation, albeit not a high degree of correlation (r 5
0.62 to 0.67) between heparin level (anti-Xa) and aPTT. At 6 h,
aPTT and heparin levels were negatively correlated with FPA
but not with F1.2, and by 24 h there was a significant relation
between higher aPTT and lower F1.2. By 24 h, the relation
between aPTT and FPA was at least as significant as that
between the heparin and FPA levels.
Relation of FPA and F1.2 with clinical outcomes. Baseline
marker levels according to 30-day survival are shown in Table
Figure 2. Relation between aPTT, FPA (A) and F1.2
(B) at 12 and 24 h, by deciles.
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3. Higher baseline levels of F1.2 were associated with a greater
likelihood of death or reinfarction (p 5 0.008). Relations of
FPA and F1.2 at 12 h with later reinfarction and death are
shown in Table 4 and Figure 3. The lower likelihood of later
reinfarction with lower levels of FPA was not significant (p 5
0.13), and survival tended to be higher with lower levels of F1.2
(p 5 0.05).
Discussion
This study reveals a series of complex relations between
pharmacologic therapy, hemostatic markers of thrombin activ-
ity and clinical outcomes. One of the major goals in the
GUSTO-I trial was to test the effect of aggressive intravenous
heparin with thrombolysis in a large trial, using the hypothesis
that more effective suppression of thrombin activity would be
important for patient outcome, especially after alteplase ther-
apy. In fact, measures of thrombin activity, albeit partially
suppressed by intravenous versus subcutaneous heparin, re-
mained elevated regardless of the heparin regimen. Moreover,
similar to the findings of Galvani et al. (13), generation of new
thrombin was increased to a similar degree with both heparin
regimens. The correlation of levels of markers of thrombin
activity with clinical outcomes lends support to the hypothesis
that these physiologic markers may play a role in reflecting
clinically important effects of antithrombotic therapy.
Hemostasis markers according to treatment group and
time. Baseline FPA levels, measured by radioimmunoassay,
were elevated to 10 times normal, similar to other reports of
patients with acute myocardial infarction (4). We found an
increase in FPA 90 min after thrombolytic therapy; the in-
crease was most pronounced in the absence of intravenous
heparin, where the 42% increase in FPA levels over baseline
was similar to the increase observed in previous reports (1,2).
In contrast to the experience of Rapold et al. (4), in which
intravenous heparin caused a decrease to the normal range in
FPA at 90 min, accelerated alteplase with concomitant full-
dose intravenous heparin was associated with a persistent
elevation in FPA, albeit less elevated than with streptokinase
and delayed subcutaneous heparin. This finding suggests only
partial inhibition of thrombin with intravenous heparin.
Direct comparison of the change in FPA from baseline to
6 h with or without intravenous heparin confirms the findings
of Galvani et al. (13), that intravenous heparin attenuates the
early increase after streptokinase, but that neither heparin
regimen fully suppresses thrombin activity.
Although heparin was expected to decrease thrombin’s
activity on fibrin formation, whether heparin would decrease
the generation of additional thrombin was less certain. Throm-
bin generation could be reduced by suppression of the feed-
back activation of factors V and VIII by thrombin, or increased
if the predominant effect is a decrease in the generation (and
inhibitory effect) of activated protein C. Similar to the findings
of Merlini et al. (14), thrombin generation (measured by F1.2)
persisted to a similar degree, independent of intravenous
heparin administration.
Similar to F1.2, TAT levels increased after thrombolysis,
most prominently among patients treated with streptokinase-
containing regimens and intravenous heparin regimens. The
TAT complex depends on available thrombin and AT-III; thus,
TAT levels would be expected to increase in concert with the
increases in F1.2 levels after thrombolysis. Because heparin
increases the affinity of AT-III to thrombin, TAT levels would
be expected to be higher among patients treated with intrave-
nous heparin. The lower levels of TAT after alteplase therapy
suggest that this plasminogen activator may result in the
exposure and availability of less thrombin than after streptoki-
nase therapy.
As expected, the reduction in fibrinogen level was more
pronounced with streptokinase-containing treatment strate-
gies. The fibrinogen level after alteplase therapy in our study
was similar to that described by Neuhaus et al. (15) and lower
than that in the Thrombolysis In Myocardial Infarction studies
using 100 mg of intravenous alteplase (16,17), suggesting more
extensive fibrinogenolysis with the accelerated dosing sched-
ule. D-Dimer, a measure of fibrin breakdown, was highest at
90 min in the alteplase group, then lowest in the same group
Table 2. Correlations Between Hemostasis Markers
F1.2 FPA TAT Heparin Xa
6-h aPTT
Corr coeff 0.04 20.25 0.47 0.64
p value 0.70 0.01 , 0.001 , 0.001
6-h heparin Xa
Corr coeff 0.04 20.26 0.38 —
p value 0.63 0.004 , 0.001
12-h aPTT
Corr coeff 20.04 20.12 0.31 0.67
p value 0.51 0.06 , 0.001 , 0.001
12-h heparin Xa
Corr coeff 20.11 20.22 0.22 —
p value 0.06 , 0.001 , 0.001
24-h aPTT
Corr coeff 20.22 20.31 0.07 0.62
p value 0.001 , 0.001 0.31 , 0.001
24-h heparin Xa
Corr coeff 20.19 20.24 0.14 —
p value 0.002 , 0.001 0.02
aPTT 5 activated partial thromboplastin time; Corr coeff 5 correlation
coefficient; F1.2 5 prothrombin fragment 1.2; FPA 5 fibrinopeptide A; TAT 5
thrombin–antithrombin complex.
Table 3. Baseline Values of Hemostasis Markers According to
30-Day Mortality or Myocardial Reinfarction
Death or MI
(n 5 24)
No Death or MI
(n 5 202) p Value
FPA (ng/ml) 16.2 (8.8, 23) 12.2 (6.2, 23.3) 0.13
F1.2 (nmol/liter) 0.42 (0.32, 0.96) 0.34 (0.25, 0.49) 0.008
TAT (ng/ml) 17.8 (14.3, 24.0) 18.7 (13.2, 26) . 0.50
Fibrinogen (mg/dl) 268 (192, 384) 260 (170, 336) . 0.44
Data presented are median (25th, 75th percentiles). MI 5 myocardial
reinfarction; other abbreviations as in Table 2.
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after 6 h, suggesting an intense early fibrinolysis with alteplase,
but a lesser effect after the first several hours. This is consistent
with clinical evidence of more potent clot lysis with accelerated
alteplase at 90-min coronary angiography (10), higher rates of
early intracranial hemorrhage (18) and more potent longer
term effects of streptokinase—higher rates of bleeding com-
plications other than intracranial hemorrhage (18) and lower
rates of reocclusion.
Correlation of hemostasis markers with outcome. Al-
though the goal of suppression of thrombin activity has a sound
pathophysiologic rationale, studies to date have been unable to
examine relations between markers of thrombin activity and
outcome because of small sample sizes. We were able to show
a relation between higher baseline levels of thrombin activity
and generation and higher 30-day mortality. We found that
higher levels of F1.2 at 12 h after thrombolysis were associated
with a trend toward a higher likelihood of later reinfarction.
Whether the worse outcomes were because the assays identi-
fied a group of patients at higher baseline risk (19,20), or
because of inadequate suppression of thrombin generation and
activity, is unknown and cannot be definitively determined
because of the small number of events. Nevertheless, the
findings that heparin does not suppress F1.2 and that F1.2 may
be related to higher risk of clinical events support the concept
that failure to inhibit thrombin generation may be a limitation
of heparin.
Correlations between heparin levels and measures of he-
mostasis. The original target aPTT was derived from a rabbit
model of jugular vein thrombosis, in which a heparin level of
0.2 to 0.4 U/ml by protamine titration resulted in effective
anticoagulation (7). For most reagents, aPTT associated with
this heparin level is in the range of 1.5 to 3.0 times the control
value. Some investigators have argued that the optimal mea-
sure of anticoagulant effect would be a more direct measure of
whether thrombin activity or thrombosis has been sup-
pressed—a measure such as FPA (21). We found a highly
statistically significant but relatively weak correlation between
aPTT and heparin levels, perhaps in part related to factors
other than heparin levels affecting aPTT after thrombolysis.
Based on the results of this study, however, aPTT appears to be
an equally good measure of target heparin range as the heparin
level itself, because aPTT correlates at least as well as the
heparin level with FPA levels at 24 h by anti-Xa assay.
Measuring heparin effect early after thrombolysis is chal-
lenging, because the systemic effect of fibrinogenolysis may
increase the aPTT, independent of its effect on thrombin. The
results of this study were consistent with this concept—there
was a weaker relation between heparin and FPA levels at 6 h
(p 5 0.01) than at 24 h (p , 0.001). The finding of a significant
relation of both higher aPTTs and higher heparin levels with
lower FPA levels, but not with lower F1.2 levels, early after
thrombolysis is consistent with the previously discussed finding
that heparin inhibits activity but not generation of thrombin.
Clinical implications. These results indicate that heparin
in conjunction with thrombolytic therapy has complex, some-
times inconsistent effects on thrombin. These findings also
suggest that if complete inhibition of thrombin and prevention
of thrombin generation are goals, heparin is not effective early
after thrombolysis. More potent direct thrombin inhibitors,
with or without agents that inhibit coagulation factors earlier in
the cascade (such as factors Xa or V inhibitors or tissue factor
pathway inhibitors), might prevent thrombin generation more
effectively.
Study limitations. Determinations of marker levels of
thrombin activity are very susceptible to artifact. The fact that
multiple centers drew, processed and handled the samples, in
spite of careful training, may have increased the likelihood of
inconsistent quality and artifact. Although femoral artery
sheaths have been found to increase FPA levels, in this study
FPA levels were similar among patients with and without
sheaths in place, suggesting that this was not a major factor.
The relatively small overall sample size is a substantial limita-
tion, particularly when attempting to correlate marker values
with infrequent outcomes. Because of the multiple compari-
sons, the absent or only borderline statistical significance of
some of the correlations and the observational nature of the
analyses, this study should not be interpreted as definitive
evidence of the effect of heparin and the significance of
markers of thrombosis, but should rather be considered sup-
portive.
Conclusions. Despite its shortcomings, this study repre-
sents the most detailed characterization to date of markers of
Table 4. Baseline Characteristics and Outcomes According to 12-h Fibrinopeptide A and Prothrombin Fragment 1.2
12-h F1.2 (nmol/liter) 12-h FPA (ng/ml)
, 0.3
(n 5 96)
0.3–0.46
(n 5 101)
. 0.46
(n 5 96)
# 5.0
(n 5 99)
. 5.0–10.6
(n 5 96)
. 10.6
(n 5 97)
Age (yr) 59 (50, 70) 61 (50, 72) 65 (54, 72) 57 (48, 70) 63 (52, 71) 63 (54, 72)
Female 29 24 34 29 27 28
Systolic BP (mm Hg) 128 (110, 143) 127 (114, 140) 122 (109, 140) 126 (110, 140) 120 (108, 135) 130 (118, 140)
Heart rate (beats/min) 73 (62, 84) 70 (74, 80) 74 (60, 88) 72 (63, 84) 70 (60, 79) 76 (64, 88)
Killip class III or IV 0 2 2 0 2 2
Anterior infarction 32 40 41 30 40 44
30-day mortality 1.1 4.0 8.7 2.2 6.4 6.3
Death or infarction 5.5 8.1 13.0 4.4 10.6 11.6
Data are presented as percentage of patients or median value (25th, 75th percentiles). BP 5 blood pressure; other abbreviations as in Table 2.
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thrombin generation and activity after thrombolytic therapy.
The findings suggest that additional studies are needed to
define the relation of both thrombin generation and activity to
clinical outcomes and to address the importance of inhibition
not only of thrombin activity but also of thrombin generation.
Appendix
GUSTO-I Hemostasis Substudy Investigators and
Study Coordinators
Scarborough General Hospital, Scarborough, Ontario, Canada: S.
Roth, J. Smith; George Washington University Medical Center, Washing-
ton, DC: A. M. Ross, K. Coyne; Maine Medical Center, Portland, Maine:
C. Lambrew, J. Kane; Tulsa Regional Medical Center, Tulsa, Oklahoma:
E. Pickering, P. Cotham; University of Michigan Medical Center, Ann
Arbor, Michigan: E. R. Bates, E. Kline-Rogers; Mother Francis Hospi-
tal, Tyler, Texas: N. Israel, R. LeBoeuf; Victoria General Hospital,
Halifax, Nova Scotia, Canada: C. Kells, T. Fawcett; University of Alberta
Hospital, Edmonton, Ontario, Canada: J. Burton, C. Kee; Proctor
Community Hospital, Peoria, Illinois: P. Schmidt, D. Miller; St. Mary’s
Hospital, Rochester, Minnesota: S. Kopecky, A. McLaughlin; Duke
University Medical Center, Durham, North Carolina: C. B. Granger, E.
Berrios.
References
1. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide
A after streptokinase: evidence of continued thrombosis despite intense
fibrinolysis. J Am Coll Cardiol 1987;10:527–9.
2. Eisenberg PR, Sherman LA, Rich M, et al. Importance of continued
activation of thrombin reflected by fibrinopeptide A to the efficacy of
thrombolysis. J Am Coll Cardiol 1986;7:1255–62.
3. Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A. Monitoring of
fibrin generation during thrombolytic therapy of acute myocardial infarction
Figure 3. Relation of 12-h FPA (A) and F1.2 (B) level
with 30-day mortality, reinfarction and combined 30-
day mortality and nonfatal reinfarction.
504 GRANGER ET AL. JACC Vol. 31, No. 3
THROMBIN ACTIVITY WITH ANTITHROMBOTIC THERAPY March 1, 1998:497–505
with recombinant tissue-type plasminogen activator. Circulation 1989;79:
980–9.
4. Rapold HJ, de Bono D, Arnold AER, et al., for the European Cooperative
Study Group. Plasma fibrinopeptide A levels in patients with acute myocar-
dial infarction treated with alteplase: correlation with concomitant heparin,
coronary artery patency, and recurrent ischemia. Circulation 1992;85:928–
34.
5. Hsia J, Kleiman NS, Aguirre FV, Chaitman BR, Roberts R, Ross AM.
Heparin-induced prolongation of partial thromboplastin time after throm-
bolysis: relation to coronary artery patency. J Am Coll Cardiol 1992;20:31–5.
6. Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M.
Correlation between level of heparinization and patency of the infarct-
related coronary artery after treatment of acute myocardial infarction with
alteplase (t-PA). J Am Coll Cardiol 1992;20:513–9.
7. Hirsh J. Heparin. N Engl J Med 1991;324:1565–74.
8. Gulba DC, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels
during thrombolytic therapy in acute myocardial infarction: relevance for the
success of therapy. Circulation 1991;83:937–44.
9. The GUSTO-I Investigators. An international randomized trial comparing
four thrombolytic strategies for acute myocardial infarction. N Engl J Med
1993;329:673–82.
10. The GUSTO Angiographic Investigators. The effects of tissue plasminogen
activator, streptokinase, or both on coronary-artery patency, ventricular
function, and survival after acute myocardial infarction. N Engl J Med
1993;329:1615–22.
11. Lawler CM, Bovill EG, Stump DC, Collen DJ, Mann KG, Tracy RP. Fibrin
fragment D-dimer and fibrinogen B beta peptides in plasma as markers of
clot lysis during thrombolytic therapy in acute myocardial infarction. Blood
1990;76:1341–8.
12. Lidon RM, Theroux P, Juneau M, Adelman B, Maraganore J. Initial
experience with a direct antithrombin, Hirulog, in unstable angina: antico-
agulant, antithrombotic, and clinical effects. Circulation 1993;88:1495–501.
13. Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg
PR. Failure of fixed dose intravenous heparin to suppress increases in
thrombin activity after coronary thrombolysis with streptokinase. J Am Coll
Cardiol 1994;24:1445–52.
14. Merlini PA, Bauer KA, Oltrona L, et al. Thrombin generation and activity
during thrombolysis and concomitant heparin therapy in patients with acute
myocardial infarction. J Am Coll Cardiol 1995;25:203–9.
15. Neuhaus KL, von Essen R, Tebbe U, et al. Improved thrombolysis in acute
myocardial infarction with front-loaded administration of alteplase: results
of the rt-PA-APSAC patency study. J Am Coll Cardiol 1992;19:885–91.
16. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy
with recombinant tissue-type plasminogen activator, heparin, and aspirin for
acute myocardial infarction: results of the Thrombolysis In Myocardial
Infarction (TIMI), Phase II trial. Ann Intern Med 1991;115:256–65.
17. Rao AK, Pratt C, Berke A, et al., for the TIMI investigators. Thrombolysis
In Myocardial Infarction (TIMI) trial—Phase I: hemorrhagic manifestations
and changes in plasma fibrinogen and fibrinolytic system in patients treated
with recombinant tissue plasminogen activator and streptokinase. J Am Coll
Cardiol 1988;11:1–11.
18. Gore JM, Granger CB, Sloan MA, et al., for the GUSTO Investigators.
Stroke after thrombolysis: mortality and functional outcomes in the
GUSTO-I trial. Circulation 1995;92:2811–8.
19. Berkowitz SD, Granger CB, Pieper KS, et al., for the GUSTO-I Investiga-
tors. Incidence and predictors of bleeding after contemporary thrombolytic
therapy for myocardial infarction. Circulation 1997;95:2508–16.
20. Lee KL, Woodlief LH, Topol EJ, et al., for the GUSTO-I Investigators.
Predictors of 30-day mortality in the era of reperfusion for acute myocardial
infarction: results from an international trial of 41,021 patients. Circulation
1995;91:1659–68.
21. Sobel BE. Intracranial bleeding, fibrinolysis, and anticoagulation: causal
connections and clinical implications. Circulation 1994;90:2147–52.
505JACC Vol. 31, No. 3 GRANGER ET AL.
March 1, 1998:497–505 THROMBIN ACTIVITY WITH ANTITHROMBOTIC THERAPY
